Tg Therapeutics Inc

$31.81 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Tg Therapeutics Inc

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Stock Analysis

last close $31.81
1-mo return 2.4%
3-mo return -16.6%
avg daily vol. 793.35T
52-week high 56.74
52-week low 21.06
market cap. $4.8B
forward pe -
annual div. -
roe -119.3%
ltg forecast -
dividend yield -
annual rev. $2M
inst own. 71.9%
baraka

Subscribe now for daily local and international financial news

Subscribe